Celltrion will supply exclusively oral-dose biologics player Rani Therapeutics with its Stelara (ustekinumab) biosimilar drug substance for use in Rani’s proposed RT-111 orally administered ustekinumab biosimilar, in a partnership that the California-based biotech says validates its RaniPill oral drug delivery technology.
Under the firms’ license and supply agreement, Rani will be granted an exclusive license to use Celltrion’s CT-P43 ustekinumab biosimilar...






